使用FDA不良事件报告系统 (FAERS) 批准用于乳腺癌的HER2抑制剂相关的不良事件的全面分析
Airi Yajima1, Yoshihiro Uesawa1
1Department of Medical Molecular Informatics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan.
Pharmaceuticals (Basel, Switzerland)
|October 29, 2025
概括
分析了人类表皮生长因子受体2 (HER2) 抑制剂的不良事件概况. 研究结果显示,单克隆抗体 (mAbs) 和氨酸激酶抑制剂 (TKIs) 的不同副作用模式,有助于更安全的治疗选择.
科学领域:
- 药监和药物安全 药监和药物安全
- 瘤学和乳腺癌治疗方法
- 在医疗保健中的数据挖掘和统计分析.
背景情况:
- 人类表皮生长因子受体2 (HER2) 抑制剂显著改善了HER2阳性乳腺癌患者的结果.
- 了解各种HER2抑制剂的独特不良事件 (AE) 概况对于顺序或组合疗法至关重要.
- 目前对HER2抑制剂中AE趋势的了解仍然不足以进行最佳的临床决策.
研究的目的:
- 综合分析和描述与不同类型的HER2抑制剂相关的不同不良事件 (AE) 概况.
- 确定与乳腺癌治疗中使用的HER2向疗法相关的特定AE信号和模式.
- 提供数据驱动的洞察力,以改善 HER2 阳性乳腺癌的药物选择和 AE 管理策略.
主要方法:
- 使用美国食品和药物管理局不良事件报告系统 (FAERS) 数据库 (2004年1月至2024年9月).
- 进行了不成比例分析,计算了与HER2抑制剂相关的AE报告几率比率 (lnROR) 的自然对数.
- 采用分层集群分析和主要成分分析 (PCA) 来根据药理类分组和区分AE配置文件.
主要成果:
- 不成比例分析发现了显著的AE信号,头发疾病是其中一个突出的例子 (ROR 39.93).
- 层次分类揭示了与药理学类相对应的独特AE集群,特别是将单克隆抗体 (mAbs) 与氨酸激酶抑制剂 (TKIs) 分开.
- 主要成分分析 (PCA) 根据AE发生风险区分了HER2抑制剂,将mAbs与TKI区分开来,并将分子向剂与抗体药物合剂分开来.
结论:
- 该研究成功地使用FAERS数据和先进的统计方法可视化了HER2抑制剂的独特AE概况.
- 研究结果表明,由mAbs和TKI分类的HER2抑制剂表现出独特的不良事件模式.
- 这些见解可以支持更安全的药物选择,风险分层以及对HER2阳性乳腺癌患者的增强AE管理策略.
关键词:
在FAERS数据库中,我们可以找到FAERS数据库.HER2 抑制剂的使用有关不良事件的个人资料.抗体药物合物 抗体药物合物乳腺癌 乳腺癌 乳腺癌集群分析集群分析集群分析分子向疗法是一种分子向疗法.这是一种单克隆抗体.主要组件分析的主要组件分析氨酸激酶抑制剂 氨酸激酶抑制剂更多相关视频
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.4K
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
674
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Hazard Ratio
558
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
558
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
397
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
397
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
